These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31350854)

  • 21. The Faces of "Too Late"-A Surprisingly Progressive Cohort of "Stable" Relapsing Remitting Multiple Sclerosis Patients.
    Ciubotaru A; Grosu C; Alexa D; Covali R; Maștaleru A; Leon MM; Schreiner TG; Ghiciuc CM; Roman EM; Azoicăi D; Ignat EB
    Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336442
    [No Abstract]   [Full Text] [Related]  

  • 22. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
    Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
    Petzold A; Steenwijk MD; Eikelenboom JM; Wattjes MP; Uitdehaag BM
    Mult Scler; 2016 Aug; 22(9):1154-62. PubMed ID: 27207456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 28. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
    Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
    Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
    Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
    Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
    Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients.
    Zeman D; Adam P; Kalistová H; Sobek O; Kelbich P; Andel J; Andel M
    Acta Neurol Scand; 2000 Feb; 101(2):89-94. PubMed ID: 10685854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in levels of oxidative stress markers and some neuronal enzyme activities in cerebrospinal fluid of multiple sclerosis patients.
    Bartova R; Petrlenicova D; Oresanska K; Prochazkova L; Liska B; Turecky L; Durfinova M
    Neuro Endocrinol Lett; 2016; 37(2):102-6. PubMed ID: 27179571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
    Sandelius Å; Sandgren S; Axelsson M; Malmeström C; Novakova L; Kostanjevecki V; Vandijck M; Blennow K; Zetterberg H; Lycke J
    Sci Rep; 2019 Nov; 9(1):17309. PubMed ID: 31754174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.